Weifa ASA: Record first-quarter revenues driven by organic growth

Wirtschaftsnachrichten (Symbolbild) ©unsplash.com

Oslo, 27 April 2017

Record first-quarter revenues of NOK 99.6 million (96.2 million)
All-organic growth of 3.6%
First quarter adjusted EBITDA of NOK 22.2 million (margin 22.3%)
Strong brands secured revenue growth and high market shares in all main categories
Product-line expansion through the launch of Paracetduo effervescent tablets and Nazamer Menthol nasal spray

Weifa ASA (OSE: WEIFA) had record first-quarter revenues in 2017 on higher sales within the categories: pain relief, cough & cold products and dermatology, which includes the Asan portfolio. Total revenues for the quarter was NOK 99.6 million, representing an all-organic growth of 3.6% compared with the same period of 2016.

EBITDA was NOK 21.2 million (NOK 16.5 million) for the first quarter after NOK 1.0 million (NOK 5.5 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (22.8%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter.

"We maintained a steady pace into 2017 with record first-quarter revenues. The launch of Nazamér Menthol and Paracetduo effervescent tablets extended our innovation track record, which together with rising demand for our main products are a key driver for our long-term growth," says CEO Kathrine Gamborg Andreassen.

Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:
http://webtv.hegnar.no/presentation.php?webcastId=51528850
http://www.weifa.no/webcast/
Questions may be submitted live during the presentation.

Please find the report and presentation for the first quarter enclosed. The report and presentation will also be made available on www.weifa.no/investor.

For further information, please contact:

Kathrine Gamborg Andreassen
CEO
+47 9517 8680
kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen
CFO
+47 9820 6355
s imen.nyberg-hansen@weifa.no

ARIVA.DE Börsen-Geflüster

Kurse

Weifa

0,00%

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire

Mehr Nachrichten zur Weifa Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.